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In vivo imagingThe translational potential of cell therapy to humans requires a deep knowledge of the interaction between
transplanted cells and host tissues. In this study, we evaluate the behavior of umbilical cord mesenchymal stromal
cells (UC-MSCs), labeled with ﬂuorescent nanoparticles, transplanted in healthy or early symptomatic transgenic
SOD1G93Amice (amurinemodel of Amyotrophic Lateral Sclerosis). The double labeling of cells with nanoparticles
and Hoechst-33258 enabled their tracking for a long time in both cells and tissues. Whole-body distribution of
UC-MSCs was performed by in-vivo and ex-vivo analyses 1, 7, 21 days after single intravenous or intracerebro-
ventricular administration. By intravenous administration cells were sequestered by the lungs and rapidly
cleared by the liver. No difference in biodistribution was found among the two groups. On the other hand,
UC-MSCs transplanted in lateral ventricles remained on the choroid plexus for the whole duration of the
study even if decreasing in number. Few cells were found in the spinal cord of SOD1G93A mice exclusively.
Nomigration in brain parenchymawas observed. These results suggest that the direct implantation in brain ventri-
cles allows a prolonged permanence of cells close to the damaged areas andmakes this method of tracking reliable
for future studies of efﬁcacy.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Over the last two decades, cell-based therapy has been evaluated
in cardiovascular, oncologic, autoimmune and neurodegenerative
diseases. In the neurological ﬁeld preclinical studies have demonstrated
the potential of stem cell injection (Lindvall and Kokaia, 2006). On the
other hand, their clinical application is still limited and controversial
(Viswanathan and Keating, 2011). Thanks to their self-renewal and
differentiation abilities, stem cells had been originally considered as a
possible tool to replace damaged cells by an initial selective migration
to the injured area and a subsequent differentiation into the affected
neurons (Bjorklund and Lindvall, 2000). Unfortunately, this fascinating
mechanism of repair rapidly faded away and the hope of an effective
care for neurodegenerative disorders by topic transplantation of highly, IRCCS — Istituto di Ricerche
ica e Farmacologia Molecolare,
iolatto).
. This is an open access article undercommitted neural stem cells and/or embryonic totipotential cells was
more and more neglected. On the contrary, there are growing evidences
of an alternative endocrine-like mechanism of action of stem cells in dif-
ferent murine models of acute and chronic neurological disorders that
does not involve any speciﬁc cell differentiation toward the neural lineage
(Silani et al., 2010; Uccelli et al., 2011, 2012). This mechanism, commonly
referred as bystander effect, is mainly based on the secretion of trophic
factors, anti-inﬂammatory cytokines, immunomodulatory agents and
soluble molecules even far from the diseased area by transplanted
cells. This experimental evidence greatly enlarged the spectrum of
potential cell candidates, in particular stromal cells derived from extra-
embryonic tissues, and paved the way to alternative systemic routes of
administrations, in addition to the intraparenchyma implantation
(Corti et al., 2004; Zhao et al., 2007; Knippenberg et al., 2012a;
Mitrecic et al., 2010;Willing et al., 2008). The possibility to performpre-
clinical studies by systemically injecting cells in the bloodstream (IV) or,
more locally intracerebroventricularly (ICV), has been adopted inmany
models of neurodegenerative disorders. All these premises prompted
the scientiﬁc community to focus the attention on the effect ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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erative disorders. In particular a large number of studies have been re-
cently carried out in mouse models of Amyotrophic Lateral Sclerosis
(ALS).
ALS is a fatal neurodegenerative disorder characterized by a selective
and widespread degeneration of lower and upper motor neurons
(Gordon, 2013; Rowland and Shneider, 2001). The main symptomatic
features of ALS are muscular atrophy, motor paralysis and difﬁculties in
speaking, swallowing, chewing and breathing (Harms and Baloh, 2013).
Respiratory failure is the most common cause of death for ALS patients,
which occurs within 3–5 years from the diagnosis (Al-Chalabi and
Hardiman, 2013). The effect of Riluzole, the only drug approved by the
Food and Drug Administration more than twenty years ago is very mod-
est in prolonging the life of patients without ameliorating their quality of
life, even lower than palliative cares (e.g. tracheostomy and invasive ven-
tilation) (Cheah et al., 2010;Musaro, 2013). For these reasons, alternative
and innovative therapeutic strategies are strongly and urgently required.
Interestingly, it has been recently reported that both the ICV and the IV
infusions of ematopoietic andmesenchymal stem cells induced a protec-
tive effect in two different models of ALS. Since no clear localization of
stem cells within the areas of degenerating motor neurons was found,
it was suggested that this was likely the response to the production of
anti-inﬂammatory and immunomodulatory factors produced by the
stem cells even far from the damaged areas (Garbuzova-Davis et al.,
2008; Canzi et al., 2012; Bigini et al., 2011).
However what is the fate of the cells in terms of biodistribution,
organ accumulation, potential target migration and clearance after a
systemic or ICV administration(s) is not clearly deﬁned due to the lack
of proper markers to track these cells in both healthy and diseased
experimental subjects.
Different strategies to follow the fate of transplanted stem cells in
preclinical models of human disorders have been reported (Wang and
Moore, 2012). In particular, the FDA approved Superparamagnetic
Iron Oxide nanoparticles (SPIOn) can provide an easily transferable
and non-invasive system to follow stem cells usingmagnetic resonance
imaging. An innovative approach to further increase the reliability of
stem cells tracking in different murine models of ALS by speciﬁcally
labeling the cytoplasm with SPIOn and the nucleus with Hoechst-33258
has been developed by our group (Canzi et al., 2012; Bigini et al., 2012).
Although this strategy enabled us to determine the interaction of various
types of fetal stem cells in several models of motor neuron degeneration
at different times points, perplexities were raised about the biocompati-
bility and the lack of cell perturbation after SPIOn internalization (Calero
et al., 2014; Li et al., 2013; Reddy et al., 2012). To overcome this problem,
ﬂuorescent, biocompatible and long lasting traceable poly (methyl
methacrylate) nanoparticles (PMMA-NPs) have been recently devel-
oped for the tracking of human amniotic ﬂuid cells by ex-vivo analyses.
The reliability of our approach was furthermore evaluated by in-vivo
studies where the co-incubation of SPIOn and PMMA-NPs conﬁrmed
the presence of the two tracers in transplanted cells for at least three
weeks after administration (Cova et al., 2013). On the basis of these re-
sults in the present study we proposed to label human umbilical cord
mesenchymal stromal cells (UC-MSCs) with PMMA-NPs, that segregate
into the cytoplasm, and with the nuclear dye Hoechst-33258 before to
inject them ICV or intravenously in both healthy and early symptomatic
SOD1G93A mice in order to track them at different time points during
the disease progression. UC-MSCswere selected because they represent
an innovative pool of MSCs, with a simpler, safer and cheaper collection
from donors compared to the bone marrow stem cells and the cord
blood mononuclear cells. In addition, mesenchymal stromal cells have
shown a strong immunomodulatory and cyto-protective activity in dif-
ferent preclinical models of acute inﬂammation (Grifﬁn et al., 2013;
Stagg and Galipeau, 2013; Uccelli et al., 2008). To optimize the tracking
procedures cells were labeled with PMMA-NPs, that segregate into the
cytoplasm, and with the nuclear dye Hoechst-33258. Two different
ﬂuorophores, Rhodamine B (RhB) and a deep infrared dye (DIR)respectively, were conjugated to NPs in order to combine in-vivo and
ex-vivo analyses. The labeling enabled us to follow the fate of sys-
temically administered UC-MSCs for a prolonged temporal window
that was hypothesized sufﬁcient for the cells to exert a therapeutic
response in SOD1G93A mice. This is the ﬁrst example in preclinical
ALS studies in which the tracking of the same type of stem cells is re-
ported by using two different ways of administration and where this
longitudinal tracking has been carried out in living mice by whole
body scanning with optical imaging system. The results obtained by
this work can be therefore considered as a robust pre-requisite to plan
future experiments in which the cell-host interaction could be easily
correlated with the therapeutic efﬁcacy, in a sort of theranostic ap-
proach, independently of the pathological model or the cell-type
utilized.
2. Materials and methods
2.1. Nanoparticles synthesis and characterization
Poly (methyl methacrylate) nanoparticles (PMMA-NPs) were used
to label stem cells thanks to their biocompatibility and to their low
level of biodegradability (Cova et al., 2013). They were obtained from
a co-polymerization between methyl methacrylate (MMA) and a
macromonomer of 2-hydroxyethyl methacrylate (HEMA) covalently
bound to RhB, through an emulsion free-radical polymerization process.
DIRwas not loaded duringNP formation due to high temperature and to
the presence radicals; therefore a post-synthesis process has been
adopted (Sitia et al., 2014).
For our investigation the following nanoparticles have been
synthesized:
• Positive 50 nm PMMA-NPs (number of NPs/ml H2O = 2.01E ∗ 1014;
polymer concentration = 50 mg/ml)
• Positive 200 nm PMMA-NPs (number of NPs/ml H2O = 4.62E ∗ 1012;
polymer concentration = 50 mg/ml)
Details on synthesis and NP characterization are reported in our pre-
vious study (Sitia et al., 2014).
2.2. UC collection and cell culture
Fresh human umbilical cords (UC) were collected from the Operating
Room of the Obstetrics and Gynecology Unit at A.O. Papa Giovanni XXIII
in Bergamo (Italy). Informed written consent was obtained from each
donor mother according to the guidelines of ethical committee of the
A.O. Papa Giovanni XXIII, as required by the clinical trial “Umbilical
Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe
Steroid-resistant Graft Versus Host Disease” (clinicaltrials.gov ID
NCT02032446) approved by “Istituto Superiore di Sanità” and “Agenzia
Italiana del Farmaco”. After cesarean sections, UC-MSCs have been iso-
lated fromwholeUCby tissuemechanical disaggregation and cultivated
as previously described (Capelli et al., 2011). Brieﬂy, the UCs were cut
into 5 cm long segments which were longitudinally cut and split open
to expose the inner surface. Each UC segment, subsequently minced
in very small fragments, was transferred into 150 mm cell culture
Petri dishes (Corning) containingMSC expansion medium consisting
of alpha-Minimum Essential Medium (MEM) (Life-Technologies)
enriched with 5% human platelet lysate obtained from healthy donors,
50 μg/ml gentamicin (Fisiopharma) and 2 UI/ml Heparin (Hospira).
They were maintained at 37 °C in a humidiﬁed atmosphere with 5%
CO2 for 6–7days afterwhich theUC tissuewas removed and the adherent
cellswere allowed to expand for an additionalweek. After approximately
14 days, the adherent cells were harvested by TrypLe Select 1X (Life-
Technologies) treatment and re-plated in T175 ﬂasks (BD Falcon) in
MSC expansion medium for further expansion.
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differentiation potential of cells have been extensively characterized
by our group as previously reported (Capelli et al., 2011).
2.3. Cell labeling
At the third passage of culture, UC-MSCs were seeded in 24-well
plates on round glass slides at two different concentrations (2000 and
6000 cells/well). After 48 h, UC-MSCs were exposed to positively
charged 50 and 200 nm PMMA-NPs with a concentration of 20 ∗ 1010
and 2.5 ∗ 1010 NPs/ml respectively. Elapsed 6, 24 and 72 h of NP incuba-
tion, the culture medium was removed, UC-MSCs were washed twice
with phosphate buffered saline (PBS) and ﬁxed in 4% paraformaldehyde
solution for 40 min. Subsequently, Hoechst-33258 dye (Sigma-Aldrich)
(2 μg/ml in PBS) was added to ﬁxed cells for 40min for nuclear staining.
At the endof incubation, glass slidesweremountedwith coverslipswith
some drops of Fluoromount mounting medium. Confocal microscopy
analysis was performed using an Olympus Fluoview microscope
BX61 with confocal system FV500, equipped with speciﬁc lasers
λexc = 405 nm, λexc = 546 nm, to visualize Hoechst-33258 and
RhB respectively. A 3D reconstruction was carried out using Imaris 5.0
(Bitplane) software. Three replicated wells were used for each concen-
tration and time of incubation in all experiments; additional slides
without NPs were added as control.
Once determined that UC-MSCs internalize more efﬁciently PMMA-
NPs of 200 nm after 24 h of incubation, a second experiment was
executed to assess the most suitable concentration of PMMA-NPs-
200 nm. Three different concentrations were tested: 1.25 ∗ 1010,
2.5 ∗ 1010 and 10 ∗ 1010 NPs/ml. The experimental protocol was main-
tained the same as above described.
2.4. Viability and growth rate
In order to evaluate a possible cytotoxic effect of PMMA-NPs-200 nm,
UC-MSCs were seeded directly on the wells and exposed to NPs as
described above. After 24 h, they were harvested and cell viability was
evaluated both by Trypan blue (Sigma-Aldrich) dye exclusion method
and by cytoﬂuorimetric analysis using FACS Canto instrument and FACS
Diva software Version 6.1.2.
Cell growth was assessed at different time-points (6, 24, 48, 72 and
120 h) in controls and double-labeled UC-MSCs as previously reported
by our group (Cova et al., 2013).
2.5. Animals
Procedures involving animals and their care were conducted in con-
formity with the institutional guidelines at the IRCCS — Institute for
Pharmacological Research “Mario Negri” in compliance with national
(Decreto Legge nr 116/92, Gazzetta Ufﬁciale, supplement 40, February
18, 1992; Circolare nr 8, Gazzetta Ufﬁciale, July 14, 1994) and internation-
al laws and policies (EEC Council Directive 86/609, OJL 358, 1, Dec. 12,
1987; Guide for the Care 1 and Use of Laboratory Animals, U.S. National
Research Council, 8th 2 edition, 2011). This speciﬁc protocol was ap-
proved by the IRCCS-IRFMN Animal Care and Use Committee (IACUC)
and then approved by the Italian “Istituto Superiore di Sanità” (code:
17/01 D Appl 3).
Transgenic mice expressing mutant human SOD1 (SOD1G93A),
originally obtained from Jackson Laboratories, crossbred with a
C57BL/6J mice strain, were chosen as ALS model, while non-transgenic
C57BL/6 mice (nTG) were used as controls. For all the experiments,
female mice at the age of 14 weeks (corresponding to the pre-onset of
clinical signs)were used andmaintained in speciﬁc pathogen free animal
rooms.
A total of seventy female mice were enrolled for the in-vivo studies.
They were divided in the following six groups: 1) SOD1G93A mice ICV
injected with UC-MSCs (n = 15); 2) nTG mice ICV injected withUC-MSCs (n = 15); 3) nTG mice ICV injected with vehicle (n = 5);
4) SOD1G93A mice IV injected with UC-MSCs (n = 15), 5) nTG mice
IV injectedwithUC-MSCs (n=15); 6) nTGmice IV treatedwith vehicle
(n = 5).
An additional group of nTgmice (n= 18)was intravenously treated
with UC-MSCs. in order to evaluate the fate of UC-MSCs in the early
hours after their administration.
2.6. Surgery and transplantation procedures
Labeled UC-MSCs were detached from the culture plates, centrifuged,
counted and resuspended in sterile PBS as previously described (Cova
et al., 2013).
Fifteen SOD1G93A female mice at age 14 weeks corresponding to the
pre-symptomatic stage and the same number of age-matched nTG mice,
anesthetized with a 5% isoﬂurane/oxygenmixture, received 250,000 cells
in the anterior horn of the brain lateral ventricles (125,000 for each side)
diluted in 8 μl (4 μl for each ventricle). The following stereotaxic coordi-
nates were utilized (Anterior Posterior 0.0 mm from the bregma;
Lateral ± 1.0 mm from the bregma; Deepness −3.0 mm from skull
surface). Five nTG animals, receiving the same volume of PBS, were
used as inner control.
The same number of animals (equally divided among SOD1G93A
and nTG mice) systemically received 1,000,000 of UC-MSCs injected in
the tail vein. Cells were diluted in 250 μl of PBS to minimize the risk of
embolism or thrombi. Five nTG animals, receiving the same volume of
PBS, were used as inner control.
Before cell administration, ﬁve animals were randomly assigned to
the experimental group sacriﬁced at 1, 7 and 21 days after injection.
Another group of 18 mice was intravenously injected with 1,000,000
of UC-MSCs and three mice per group were sacriﬁced at 1, 3, 6 h,
1 day and 5 days after cell administration to evaluate the distribution
of the cells in the whole body.
2.7. In-vivo and ex-vivo imaging
In-vivo whole body ﬂuorescence scanning was performed in living
SOD1G93A and nTG mice at 1, 7 and 21 days from UC-MSC administra-
tion as previously described (Sitia et al., 2014; Bigini et al., 2014). Thanks
to DIR dye, bounded to the PMMA-NPs, we were able to track UC-MSCs
with minimal tissue background and high optical contrast. The Explore
Optix System (ART Advanced Research Technologies, Montreal, Canada)
and a ﬁxed pulsed laser diode as an illumination source was used as
already described by our group (Bigini et al., 2014). Excitation was per-
formed with a 735 nm pulsing laser and emission was detected with a
755 nm long pass ﬁlter.
Immediately after the mice were sacriﬁced, ex-vivo optical scan of
the isolated kidney, spleen, liver, lung, heart, brain, spinal cord and
muscle was carried out to better understand the actual accumulation
of signal in each single organ before proceeding with the histological
analysis.
2.8. Histological analyses
The brain, spinal cord, lung, kidney, liver, heart, spleen and muscle
were rapidly collected, frozen in dry ice and maintained at−80 °C until
their use.
Sectionswith a thickness of 30 μmwere obtained after cryostat cutting
and observed with a BX81 microscope equipped with an F-view II CDD
camera (Olympus).
2.9. Data calculation and statistical analysis
The percentage of cell viability after NP incubation is reported as
mean ± S.D. and analyzed by the unpaired Student's t-test. P values
≤0.05 was considered as threshold to establish a statically signiﬁcant
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with Bonferroni post-test analysis, was carried out to compare the
trend of proliferation of cells with or without double labeling with
PMMA-NPs and Hoechst-33258.
All statistical analyses were done using the GraphPad Prism version
4.00 for Windows (Graph-Pad Software, San Diego, CA, USA).Fig. 1. Representative confocal microscopy images showing A) UC-MSCs incubated for 6, 24 and
incubated for 24 h with three different concentrations of 200 nm PMMA-NPs. The red signal is
C) UC-MSCs incubated with PMMA-NPs after 24 h. D) 3D reconstruction of treated cells is repo3. Results and discussion
3.1. In-vitro results
The ﬁrst requirement in experiments of cell labeling is the fast and
efﬁcient internalization of tracers in the target. To verify it, the rate of72 hwith 50 nm (upper panel) and 200 nm (lower panel) large PMMA-NPs; B) UC-MSCs
associated with NPs; the blue staining is associated with the nuclear dye Hoechst-33258.
rted at low and high magniﬁcations.
Fig. 2. A) Analysis of size (FSC) and granularity (SSC) of UC-MSCs before and after the
incubation with three different concentrations of PMMA-NPs. B) Effect of different
concentration of 200 nm PMMA-NPs on UC-MSC. Cell viability was determined by Trypan
blue dye exclusionmethod. Data are expressedmean± S.D. and analyzed by the unpaired
Student's t-test.
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bating UC-MSCs 6, 24 and 72 h with PMMA-NPs. Hoechst-33258 was
used to label cell nuclei. NPs of two different sizes were tested (50 and
200 nm large NPs) in order to establish the more efﬁcient labeling
agent. Representative images showing the distribution of both 50 and
200 nm large NPs at the three different time points are reported in
Fig. 1A. As expected, the Hoechst-33258 nuclear labeling (visualized
in blue) was already at the maximum levels at the ﬁrst time point of
analysis and remained stable for the whole observation. In contrast,
NP internalization was a slower process that progressively increased
over time. In particular, the staining for 50 nm large PMMA-NPs was
almost undetectable up until one day of incubation and the interaction
for three days produced a very weak signal (Fig. 1A, upper panels). On
the contrary, cell incubated with 200 nm large PMMA-NPs resulted in
a much higher ﬂuorescent signal. At 6 h, a strong NP signal was already
detectable in incubated cells and it was mainly conﬁned to the periph-
eral region of the cytoplasm. At later time points, NPs progressively in-
ternalized and uniformly occupied the whole cytoplasm (Fig. 1A lower
panels). Recent studies, performed by our group, have shown that the
NP size did not greatly inﬂuence the number of NPs internalized in
cells (Sitia et al., 2014; Ferrari et al., 2014). This evidence strongly
suggests that the difference among the two types of NPs is mainly due
to the higher amount of RhB for each single NP in 200 nm large NPs.
In addition, we found that larger NPs are more efﬁciently enwrapped
in inert endosomes and stay for a longer time in host cells without
any relevant perturbation. For these reasons, we decided to carry on
the experiments using 200 nm large PMMA-NPs and stopping the incu-
bation at the 24th hour (where the cellular signal associated with RhB
was evident for almost all cells and the background was nearly absent).
Once ﬁxed the size of NPs and the length of incubation to be used, a
dose response experiment was carried out to verify themost appropriate
NP concentration. As depicted in Fig. 1B, already with the lower concen-
tration [1.25 ∗ 1010 NPs/ml] a uniform and strong labeling was induced.
Higher concentrations did not increase either the percentage of labeled
cells or the speciﬁc signal intensity. On the other hand, a strong non-
speciﬁc NP-related signal was observed at the highest dose.
The optimization of the procedure of stem cell labeling was neces-
sary to deﬁne a protocol for in-vivo and ex-vivo tracking. We found an
efﬁcient labeling of all cells 24 h after NP incubation. Opposite the
prolonged incubation did not increase intracellular staining but led to
membrane not speciﬁc staining. Positively charged polymeric NPs
rapidly undergo to an electrostatic attraction to the outer portion of
the cell membrane, this interaction leads to vesicle formation and con-
sequent cytoplasmic endocytosis of NPs segregated in this vesicles
(Sahay et al., 2010). This process occurs in the ﬁrst hours of incubation
and progressively decreased probably for the lack of the vesicle avail-
ability. This biological limit may therefore cause the accumulation of
NPs to the external surface without an efﬁcient endocytosis and their
consequent risk of a rapid leakage in the biological ﬂuids after their in-
jection (Duan and Li, 2013; Shah et al., 2012). Freely circulating NPs in
plasma rapidly interact with immunocompetent cells, reticulocytes,
Kupffer cells in the liver and splenicmacrophages. For this reason to fur-
thermore reduce the presence of false negative (due to the staining of
host cells that have uptake free circulating NPs) we also included the
nuclear marker Hoechst-33258 as previously reported (Bigini et al.,
2012; Cova et al., 2013). However, this procedure should be always
guaranteed by an earlier control of the effective cellular internalization
of NPs at least until the time of inoculation.
A more detailed representation of tracer localization in UC-MSCs is
shown in Fig. 1C where the same ﬁeld-of-view is depicted in four differ-
ent manners, 24 h after incubation. In the left-up image the shape of
plated cells using the interferential contrast (Nomarski) can be observed;
in the left-bottom image the signal from the channel associated with
Hoechst-33258 is shown revealing the segregation of such marker in
the nuclear region as expected. Most importantly, the merge image re-
vealed that the signal associated with NPs (red) does not co-localizewith blue nuclear staining and it is conﬁned to the cell surface. A repre-
sentative 3D scanning of double labeled UC-MSCs is shown in Fig. 1D.
In the upper panel, a low magniﬁed picture enhances the contrast and
the separation among the two tracers; the lower panel is of interest to un-
mask the clear contiguity between NPs and Hoechst-33258 without any
superimposition. This is in line with our recent results showing that
PMMA-NPs rapidly diffused toward the cytoplasm mainly localizing to
the perinuclear region (colocalization with Golgi apparatus and endo-
plasmic reticulum has been demonstrated) (Sitia et al., 2014).
The possible cellular perturbation of size (FSC) and granularity (SSC)
after NP incubation was measured by FACS analysis. Fig. 2A shows the
presence of a morphologically distinct cell population (P1, red) in cells
exposed to NPs. The cluster of cells included in P2 (green) showed
size and granularity typical of these mesenchymal cells. The P1 group
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indicated changes of cellular complexity due to a partial change in the
internal morphology and in the surface roughness of the cell after
vesicles-dependent NP internalization (Sitia et al., 2014). FACS analysis
conﬁrmed the previous results shown in Fig. 1B. In addition, no signiﬁ-
cant difference on cell survival was detectable 24 h after NP incubation
for each concentration used, compared to untreated cells (Fig. 2B). The
analysis of cell proliferation revealed a similar trend of growth rate for
both unlabeled and double labeled cells. Both experimental groups
showed a ﬁrst phase (0 to 24 h) ofmild increase of rate. At the following
time, until the 72nd hour, the slope of the growth was higher for both
groups. From the 72nd to the 120th hours the growth rate slightly
decreased. However this reduction in growth rate at the latter time-
point could be likely due to the conﬂuence on the plate. Neither the
analysis of variance nor the student t-test at each single time-point
revealed difference among the two experimental groups. This result
further suggests that the labeling did not markedly alter the cell
physiology.
All these results, in agreement with previous studies (Cova et al.,
2013; Srivastava and Bulte, 2014), allowed us to exploit this safe and ef-
ﬁcient procedure of labeling to follow the fate of transplanted UC-MSCs
in mice.
3.2. In-vivo results
Based on the in-vitro analysis, the concentration of 1.25 ∗ 1010 NPs/ml
of PMMA-NPs-200 nmwas chosen for the in-vivo studies. Representative
images of ﬂuorescence distribution by in-vivo Optical Imaging in both
SOD1G93A and nTG mice are reported in Fig. 3A. Due to the high level
of autoﬂuorescence of tissues in the visible wavelengths (associated to
RhB), the presence of the DIR dye (λ= 735 nm) allowed us to improve
the signal/background ratio thus optimizing the quality and the reliability
of in-vivo imaging observations. The laser power was ﬁnely tuned in
order to avoid as much as possible the non-speciﬁc signal of the tissue
using mice treated with vehicle alone (see Fig. 3A left panel). One day
after IV administration of UC-MSCs a strong signal was spread in the
thoraco-abdominal area. In particular, an intense signal was found close
to the region corresponding to the lungs (top) and liver (bottom).
Seven days after cell injection, a similar pattern of signal distribution,
even if of lower ﬂuorescence intensity (FLI), was observed. A drastic re-
duction of FLI was instead observed three weeks after UC-MSC adminis-
tration. The overall FLI pattern registered was nearly overlapping amongFig. 3. A) In vivo near-infrared ﬂuorescent scans of SOD1G93A (upper panel) and nTG mice
acquired before (vehicle) administration, and at different time points (1, 7 and 21 days) after st
counts (NC), is shown as a pseudo-color scale bar. B) Temporal point-spread function (TPSF) a
injection. Both SOD1G93A and nTG mice show the same curve. C) Ex vivo biodistribution an
and 21 days). At each time point, the signal derived from the excised organs was quantiﬁed an
was normalized to 1.the ﬁve mice tested for each experimental group, indicating good homo-
geneity in the stem cell localization. The pattern of distribution and FLI
was similar between SOD1G93A and nTG mice.
To better assess if the signal was actually independent on the auto-
ﬂuorescence, a quantitative analysis of the speciﬁc signal was carried
out through the evaluation of the Temporal Point-Spread Function
(TPSF). This parameter is unequivocally correlated to the different signals
(e.g. speciﬁc signal from tissue autoﬂuorescence) discriminating them on
the base of their amplitude and the slope of the curves. Representative
TPSF proﬁles from a well-deﬁned point of the abdominal region from a
control mouse (green) and three SOD1G93A mice sacriﬁced 1 (yellow),
7 (red) and 21 (blue) days after UC-MSCs injection are shown in Fig. 3B.
The strong difference between the curves of the mice at 1 and 7 days
and the vehicle further conﬁrms that the ﬂuorescent signal observed in
the scanning area is correlated to the presence of DIR-loaded NPs. On
the other hand, this difference strongly decreased in animals sacriﬁced
21 days after transplantation.
Ex-vivo Optical Imagingwas then carried out after themice sacriﬁce
to determine the organ speciﬁcity of the signal. The FLI measurements
for lung, spleen and liver are shown in Fig. 3C. A progressive decay of
FLI was observed for both experimental groups. No signal was found
in kidneys, heart, brain, spinal cord and muscle (data not shown).
These results are consistent with the anatomical distribution of the sig-
nal observed in living mice and conﬁrm the reliability of this system of
in-vivo stem cell tracking. Two main advantages should be underlined
in comparison to other imaging technique, such as MRI to detect cells
incubated with SPIOn or ultrasounds coupled photoacoustic analysis
to reveal cells incubated with gold NPs (Jokerst et al., 2012; Bull et al.,
2014). The ﬁrst is that ﬂuorescent polymeric NPs can be directly tracked
in organs by visualizing their ﬂuorescence in histological sections in
preclinical studies to correlate easily and rapidly in-vivo and ex-vivo
analyses. The second, andmost important, is the possibility of easilymod-
ulating their biodegradability and avoids risks of NP bio-accumulation in
case of repeated stem cell administrations. This will be of fundamental
relevance in future translational studies that might open the way toward
a clinical application of this approach in different clinical ﬁelds.
The labeling of human adult mesenchymal stem cells (hMSCs) with
near-infrared dye has been recently used for their tacking after intrana-
sal administration in rats (Bossolasco et al., 2012). In that study, the
signal related to hMSCs was only detectable few minutes after applica-
tion to completely disappear into the scanned area (brain, head and
neck) within 1 h. This rapid clearance may be due to the efﬁcient(lover panel) intravenously treated with labeled UC-MSCs. Representative images were
em cell administration. The ﬂuorescence signal intensity, measured as normalized photon
cquired from the untreated mouse to the mice sacriﬁced 1, 7 and 21 days after UC-MSCs
d accumulation of UC-MSCs in the liver, lung and spleen before and after injection (1, 7
d expressed as relative ﬂuorescent intensity (FLI). The value of the vehicle treated animals
249M.B. Violatto et al. / Stem Cell Research 15 (2015) 243–253metabolismand the tropism to ﬁlter organs, in particular the lungs, after
systemic administration ofmesenchymal cells or related to a rapid leak-
age through plasmatic membrane and consequent biological elution
(Nystedt et al., 2013; Vaegler et al., 2014; Tenuta et al., 2011; Zoja
et al., 2012).
Histological analyses were carried out to conﬁrm the association
between ﬂuorescent signal and the actual presence of UC-MSCs with a
higher degree of resolution. Representative images of the lungs (leftFig. 4.A)Histological sections of lung, spleen and liver from SOD1G93A (upper panel) and nTG (
parenchymaderived frommice sacriﬁced immediately, 1 h, 3 h, 6 h, 1, and 5 days afterUC-MSCs
associated with PMMA-NPs and the blue spot is referred to UC-MSC nuclei.column), spleen (middle column) and liver (right column) from both
SOD1G93A (upper panels) and nTG mice (lower panels) are shown one
day after UC-MSC transplantation in Fig. 4A. Seven and 21 days after IV
administration no speciﬁc signal was detectable from histological
sections in both nTG and SOD1G93A mice (data not shown). In red and
in blue the signal of NPs and the nuclear dye Hoechst-33258 can be ob-
served respectively. No relevant difference in terms of NP distribution
was observedwithin the two experimental groups, in all analyzed organs.lower panel)mice sacriﬁced 1 day after UC-MSCs injection. B)Histological sections of lung
injection. The green staining is related to the autoﬂuorescence of tissues. The red staining is
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found uniformly distributed throughout all the parenchyma. The
injected cells maintained their perfect integrity as demonstrated by
the fact that the red (cytoplasm) and the blue (nuclei) signals remain
contiguous.
Several studies have shown that the majority of IV-administered
cells, especially MSCs, are trapped within the lungs at least during the
acute phase after administration (Fischer et al., 2009; Schrepfer et al.,
2007). Different key factors may inﬂuence this entrapment, such as
the kind, the size and the adhesion capacity of the injected cells. The
mean diameter of adult mouse pulmonary capillaries is approximately
15 μm, and larger cells are consequently trappedwithin the lungs. In ad-
dition, it is reported that UC-MSCs express high levels ofα4 integrin,α6
integrin andﬁbronectin: this cell surface proﬁle contributes to the adhe-
sion on the alveolar endothelium (Ruster et al., 2006).
In our experimental condition, UC-MSCs almost exclusively accumu-
lated in the lungs, and gradually moved to the reticuloendothelial
organs. In both spleens, where the signals are conﬁned in the lymphoid
follicles, (Fig. 4A, middle panels) and liver (Fig. 4A, right panels), the
NP-related signal (red) was clearly separated from the nuclear dye
Hoechst-33258. Therefore, it is clear that a very high percentage of
intravenously injected UC-MSCs are rapidly and efﬁciently captured
by the lungs before reaching the ﬁlter organs (spleen and liver) for
their metabolism and clearance. In fact, while in the lung parenchyma
the cells were still present one day after the treatment and their integ-
rity was conﬁrmed histopathologically by the contiguity of the two
markers (red for NPs and blue for nuclei), in the spleen and in the
liver there were only cellular debris and free nanoparticles (Fig. 4A).
Even in the ﬁrst 6 h when the labeled UC-MSCs were clearly visible in
the lung (Fig. 4B), no cells were noticed in the spleen and liver (data
not showed).
As regards other organs, no cells were observed in kidney sections in
both experimental groups and for each time-points considered, in line
with the lack of signal found in ex-vivo Optical Imaging analysis. More-
over, no speciﬁc UC-MSC related signal was detected in brain cortex,
brainstem, spinal cord and muscles of SOD1G93A mice that, in theFig. 5. A) Schematic representation of UC-MSC biodistribution after intravenous injection. B) S
analysis was carried out in different organs, animals and time points. – none, +/− very few (rpresent study, were followed from the 14th week to the 17th week of
life corresponding to the early phase of the disease progression (Doble
and Kennel, 2000). The same result was found for age-matched nTG
mice. The observation of numerous sections from the different organs
allowed us tomake a semiquantitative analysis of the localization, accu-
mulation and clearance in different organs of intravenously treated
mice (Fig. 5B).
Themain results emerging from this results are that: 1) intravenously
injected UC-MSCswerewell tolerated by both healthy and neurologically
affected mice; 2) UC-MSCs mainly accumulated in the lungs and rapidly
faded away without any problem of accumulation; 3) the pathological
state neither induced a selective migration of UC-MSC toward affected
areas nor altered their half-life; 4) the triple systems of tracking
exploiting three different optical proﬁles is resulted particularly
performing and reliable for a whole body screening.
A relevant aspect of using labeling agents in cell-based therapy
regards their safety. In fact, both potential health risks for ﬁnal
hosts and possible effects on the cells due to their labeling, should
be avoided at preclinical and clinical level. SPIOn has been widely
used for stem cell tracking and several published studies showed their
reliability in terms of low toxicity proﬁles. For these reasons, they
have been considered to be inert and biocompatible for a long time
(Bull et al., 2014).
However, an even more growing body of evidence is showing iron
accumulation could impair cell viability by damaging cell membranes,
misfolding proteins, inducing mitochondrial function impairment, DNA
strand breaks, ROS generation and cytoskeleton alterations (Mahmoudi
et al., 2012). In this context, it has been recently demonstrated that
SPIOn loading inhibited cell growth, proliferation rates and motility
(Diana et al., 2013). In spite of these pitfalls, MRI still remains one of
themost suitable techniques for in-vivo longitudinal tracking of adminis-
tered stem cells in mice due to its high spatial resolution and deep tissue
penetrance.
However, alternative methods, such as the use of Optical Imaging
technique, coupled to ﬂuorescent NPs, may be preferred for its higher
sensitivity, the possibility to easily generate a quantitative correlationcores associated with cell distribution after intravenous administration of UC-MSCs. The
are), + few, ++ relevant, ++++ high.
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in regions where endogenous iron is already relevant, (such as in the
spleen where the visualization of SPIOn labeled cells is impaired) and,
last but not least, the rapid analysis of the whole body, should not be
neglected (Sutton et al., 2008). The lack of relevant side-effects and
the survival of all mice conﬁrmed the high degree of biocompatibility
of PMMA-NPs for stem cell tracking experiments.
We observed that once injected in the bloodstream, the cells mainly
localized in lung parenchyma and to a lesser extent in the spleen and
liver. However, the clearance of the cells was rapid and, seven days
after the treatment, their number was found drastically reduced and
no accumulation was registered.
Even if intravenous approach would be ideal, given easy access,
questions have been raised due to the poor survival of grafted cells
after pulmonary ﬁrst-pass effect. This phenomenon may preclude the
efﬁcacy of the stem cells in a chronic disease such is the ALS.
To overcome this limit, different strategies could be applied. Several
groups are developing biocompatible scaffolds loaded with stem cells,Fig. 6. A) Anatomical detail of the injection site of UC-MSCs during intracerebroventricular tran
aggregates found into the lateral ventricles of treatedmice (lower pictures). B) Representative
nTG mice sacriﬁced after 1, 7 and 21 days from cell administration. (LV = Lateral ventricle, CP
exclusively 1 day after SOD1G93A mice were sacriﬁced.based on local controlled delivery and introduced in animals using
minimally invasive surgical procedures (Wong et al., 2014). Moreover,
other recent studies reported the possibility to subcutaneously inject
stem cell encapsulated in Alginate (Zanotti et al., 2013). This procedure
prevents possible risks related to cell transplantation (tumor growth,
graft rejection or uncontrolled differentiation) and permits a precise
dosage released over time. These systems could provide cell local release
able to reduce systemic side effects or excessive cell elution through the
body, concentrating the treatment efﬁcacy in the pathological areas to
improve stem cell therapy of neurological disorders.
Another approach could be themultiple dosing of stem cells (weekly
administrations) already evaluated in different models of neurodegen-
erative disorders, including ALS (Garbuzova-Davis et al., 2012).
Multiple transplantations could provide long-term therapeutic
effects than single transplantation, this approach can be used in future
clinical studies. In the last decade the effect of human cord bloodmono-
nuclear cells (HuCB-MNCs) transplantation has been carried out in
different mouse models, with different schedule treatments and bysplantation (upper picture); high magniﬁcation confocal images referring to the UC-MSC
images showing the localization of double labeled UC-MSCs in the brain of SOD1G93A and
= Choroid plexus) C) Sporadic clusters of UC-MSCs found in cervical spinal cord sections
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Davis et al., 2003; Knippenberg et al., 2012; Souayah et al., 2012). Quite
interestingly, the transplantation of HuCB-MNCs in the cerebral lateral
ventricles or in the bloodstream in transgenic SOD1G93A mice showed
a similar pattern of clinical and neuropathological beneﬁts mainly char-
acterized by an overall delay in symptoms progression, anti-
inﬂammatory activity and increased lifespan (Garbuzova-Davis et al.,
2008; Bigini et al., 2011; Garbuzova-Davis et al., 2012). This result fur-
ther conﬁrmed that neuroprotective effect may be ascribed by a wide
range of cells, sharing the ability to respond to stress conditions by ex-
pressing and releasing therapeutic factors.
In this context, to make a comparative evaluation on the behavior of
UC-MSCs in murine model of ALS, an extensive investigation on the
distribution of UC-MSCs after ICV transplantation has been undertaken
in this study at the same time-points reported for IV analysis but using a
lower number of cells. Fig. 6A shows UC-MSCs (middle and lower
panels) 1 day after lateral brain ventricle administration (upper panel)
in a SOD1G93A mouse. A strong signal associated with Hoechst-33258
and RhB clearly indicates the presence of a cluster of UC-MSCs arranged
to form large spherical aggregates, inside the lateral ventricle. Higher
magniﬁed picture (bottom) furthermore conﬁrms the segregation
between the two markers as previously shown by in-vitro analysis
(Fig. 1).
A representative pattern of longitudinal UC-MSC distribution in
SOD1G93A (left column) and nTG mice (right column) is shown in
Fig. 6B. One day after transplantation, injected cells remain in the site
of administration, localizing in the lateral ventricles and slightly in the
other more caudal ventricular structures. One and three weeks after
UC-MSC injection, the size and the number of events forming these
cell clusters markedly decreased, even if each single remaining cell was
still detectable. No cell has been detected into the brain parenchyma,
while observation of spinal cord slices revealed only isolated positive
cells localized both in the parenchyma and in the external surface, prob-
ably associated with meningeal layers (Fig. 6C).Fig. 7. A) Schematic representation of UC-MSC biodistribution after intracerebroventricular inje
with cell distribution after intracerebroventricular administration of UC-MSCs. The analysis w
+ few, ++ relevant, +++ high.In agreement with our previous studies (Canzi et al., 2012; Bigini
et al., 2011), we observed a very limited number of events inside the
spinal cord. This phenomenon may be associated with anatomical and
structural limitations that prevent the migration of cell aggregates in
this area. In animals sacriﬁced 21 days after implantation, there is still
a mild signal related to the cells only associated with the walls of the
ventricles and the choroid plexus, signiﬁcantly reduced compared to
the other two timelines. No substantial differences were observed be-
tween the experimental groups (nTG and SOD1G93Amice). A summary
of the results obtained by the observation of a large number of sections
is shown in Fig. 7.
In conclusion, tracking these cells with biocompatible, well tolerated
and stable NPs represents a great advantage during in-vitro, in-vivo and
ex-vivo analyses. In particular, in-vivo Optical Imaging after UC-MSC in-
travenous injection has showed very satisfactory results. This technique
provides non-invasive, localized and quantitative information regarding
biodistribution, accumulation and clearance. It allows follow-up studies
to be carried out within the same experimental subject contributing in
reducing the number of animals. Even if Optical Imaging showed
lower degree of spatial resolution in living tissues when compared
with other types of imaging modalities such as MRI, it is more sensible
and suitable for each kind of tissue.
The route of administration may surely inﬂuence the efﬁcacy of stem
cell therapy. IV injection differs from ICV injectionwith respect to cellular
distribution and number of cells still viable overtime. If after systemic
injection pulmonary sequestration may cause cell death within 1 day
after treatment, probably the most appropriate way of administration
to evaluate UC-MSC therapeutic effect is the application to the cerebro-
spinal ﬂuid.
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